Business, energy, technology, markets and global industry news from Business News Today

Almirall

PharmaDeviceNews Almirall
Almirall’s collaboration with CrystalO targets novel ion-channel small molecules for medical dermatology, expanding the company’s drug discovery strategy and early-stage dermatology pipeline. Representative image.
Pharma & Biotech

Why Almirall’s latest China biotech deal could open a new small-molecule route into dermatology

Almirall partners with CrystalO on ion-channel small molecules for dermatology. See why clinical proof of concept is the real test for the deal.

Read More
Paediatric atopic dermatitis assessment as Almirall’s Ebglyss label-expansion filing enters European Medicines Agency review. Representative image.
Pharma & Biotech

Could Ebglyss challenge Dupixent in younger children? Almirall clears a crucial EMA filing hurdle

Almirall’s Ebglyss paediatric filing enters EMA review, opening a potential path into Europe’s childhood atopic dermatitis market.

Read More
Representative image: A modern dermatology research laboratory scene illustrating Almirall’s Q1 2026 growth momentum, as Ebglyss and Ilumetri strengthen its biologics-led medical dermatology strategy in Europe.
Pharma & Biotech

Can Almirall turn dermatology momentum into a stronger long-term innovation engine?

Almirall’s dermatology engine is growing faster than group sales. The next test is whether biologics and pipeline bets can sustain momentum.

Read More
Pharma & Biotech

Sinomune to launch Almirall’s Seysara in China: Can it reshape acne treatment models?

Almirall’s Seysara gains NMPA approval for acne in China. Find out what this means for dermatology antibiotics, access, and Sinomune’s market role.

Read More